Reports Q3 revenue $103.5M, consensus $101.36M. Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “This has been a monumental quarter for Amicus highlighted by the U.S. and U.K. approvals of Pombiliti and Opfolda, the global launches of Pombiliti and Opfolda, as well as the continued strong growth of Galafold worldwide. We are now approved in the three largest Pompe markets and are making tremendous progress on our second commercial launch. In addition to the commercial successes, we are well on track to achieve all of our annual strategic priorities, including non-GAAP profitability in the fourth quarter. I am proud of everyone at Amicus who has worked so hard to make a difference in the lives of people living with rare diseases.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FOLD:
- Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
- FOLD Upcoming Earnings Report: What to Expect?
- Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
- Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
- Biotech Alert: Searches spiking for these stocks today